Inactive Instrument

LEIE ACQUPAR

Equities

LACQ

US52539T1079

Biotechnology & Medical Research

Leisure Acquisition Corp. Reports Earnings Results for the Second Quarter Ended June 30, 2019

August 07, 2019 at 05:02 pm EDT

Leisure Acquisition Corp. announced earnings results for the second quarter ended June 30, 2019. For the second quarter, the company announced operating loss was USD 625,938 compared to USD 311,538 a year ago. Net income was USD 418,902 compared to USD 415,110 a year ago. For the half year, operating loss was USD 815,112 compared to USD 481,672 a year ago. Net income was USD 1.194 million compared to USD 821,176 a year ago.

Latest news about LEIE ACQUPAR

Ensysce Biosciences Closes on Merger with Leisure Acquisition Corp.	21-06-30	MT
Ensysce Biosciences, Inc. completed the acquisition of Leisure Acquisition Corp. from HG Vora Capital Management, LLC and others in a reverse merger transaction.	21-06-29	CI
Leisure Acquisition Corp. Announces Board Appointments	21-06-29	CI
Leisure Acquisition Corp. Reports Earnings Results for the First Quarter Ended March 31, 2021	21-06-08	CI
Leisure Acquisition Corp.(OTCPK:LACQ) dropped from NASDAQ Composite Index	21-06-02	CI
Leisure Acquisition Corp. Reports Earnings Results for the Full Year Ended December 31, 2020	21-03-15	CI
Leisure Acquisition : to Pursue Merger With Ensysce Biosciences	21-02-01	MT
Leisure Acquisition Corp. Enters into Merger Agreement for Business Combination with Ensysce Biosciences, Inc. and Announces Executive Changes	21-02-01	CI
Ensysce Biosciences, Inc. entered into a definitive agreement to acquire Leisure Acquisition Corp. from HG Vora Capital Management, LLC and others for approximately $220 million in a reverse merger transaction.	21-01-31	CI
Leisure Acquisition Corp. Reports Earnings Results for the Third Quarter Ended September 30, 2020	20-11-09	CI
Leisure Acquisition Corp. Reports Earnings Results for the Second Quarter Ended June 30, 2020	20-08-07	CI
Gateway Casinos & Entertainment Limited cancelled the acquisition of Leisure Acquisition Corp. in a reverse merger transaction.	20-07-15	CI
Leisure Acquisition Corp. Reports Earnings Results for the First Quarter Ended March 31, 2020	20-05-07	CI
Leisure Acquisition Corp. Reports Earnings Results for the Full Year Ended December 31, 2019	20-03-10	CI
Leisure Acquisition Corp. announced that it expects to receive $1 million in funding from Hydra Management, LLC, Matthews Lane Capital Partners LLC, HG Vora Capital Management, LLC	20-01-14	CI
Transcript : Leisure Acquisition Corp., Gateway Casinos & Entertainment Limited - M&A Call	20-01-07
Gateway Casinos & Entertainment Limited entered into definitive agreement to acquire Leisure Acquisition Corp. in a reverse merger transaction.	19-12-26	CI
Leisure Acquisition Corp. Reports Earnings Results for the Third Quarter Ended September 30, 2019	19-11-07	CI
Leisure Acquisition Corp. Reports Earnings Results for the Second Quarter Ended June 30, 2019	19-08-07	CI
Leisure Acquisition Corp. Reports Earnings Results for the First Quarter Ended March 31, 2019	19-05-07	CI
Leisure Acquisition Corp. Reports Earnings Results for the Full Year Ended December 31, 2018	19-03-11	CI
Certain Common Stock of Leisure Acquisition Corp. are subject to a Lock-Up Agreement Ending on 30-MAY-2018.	18-05-29	CI
Leisure Acquisition Corp.(OTCPK:LACQ) added to NASDAQ Composite Index	18-02-27	CI
Leisure Acquisition Corp. has completed an IPO in the amount of $200 million.	17-12-01	CI
Leisure Acquisition Corp. has filed an IPO in the amount of $250 million.	17-11-03	CI

Chart LEIE ACQUPAR

Duration

Period

More charts

Company Profile

Ensysce Biosciences, Inc., formerly Leisure Acquisition Corp., is a clinical-stage biotech company. The Company is engaged in the development of small and large molecule drug delivery platforms targeting pain and cancer markets. The primary focus of the Company is its small molecule program developing abuse and overdose resistant pain technology with a clinical stage program being the abuse resistant, trypsin activated abuse protection (TAAP) opioid product candidate, PF614. In addition, the Company is developing multi-pill abuse resistant (MPAR) technology for overdose protection. The Company has also developed a delivery platform for large biomolecules utilizing single walled carbon nanotubes (SWCNT) to produce immunology and gene therapy products.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IQVIA HOLDINGS INC.	+2.68%	42.75B
LONZA GROUP AG	+47.70%	41.61B
MODERNA, INC.	+12.12%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.09%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-22.85%	18.12B
MEDPACE HOLDINGS, INC.	+31.36%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.33%	11.76B
UNITED THERAPEUTICS CORPORATION	+8.54%	11B

Other Biotechnology & Medical Research